{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:34:02Z","timestamp":1780767242856,"version":"3.54.1"},"reference-count":313,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"NIH Medical Scientist Training Program T32","award":["GM07170"],"award-info":[{"award-number":["GM07170"]}]},{"name":"John W. and Jeanne M. Rowe Center for Research in Virology"},{"DOI":"10.13039\/100000936","name":"Gordon and Betty Moore Foundation","doi-asserted-by":"publisher","award":["GBMF 4552"],"award-info":[{"award-number":["GBMF 4552"]}],"id":[{"id":"10.13039\/100000936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"HHS | NIH | National Human Genome Research Institute","doi-asserted-by":"publisher","award":["R01 HG010067"],"award-info":[{"award-number":["R01 HG010067"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mSystems"],"published-print":{"date-parts":[[2023,4,27]]},"abstract":"<jats:p>The development, production, and distribution of vaccines is imperative to saving lives, preventing illness, and reducing the economic and social burdens caused by the COVID-19 pandemic. Vaccines that use cutting-edge biotechnology have played an important role in mitigating the effects of SARS-CoV-2.<\/jats:p>","DOI":"10.1128\/msystems.00927-22","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T14:00:44Z","timestamp":1677765644000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":21,"title":["Application of Traditional Vaccine Development Strategies to SARS-CoV-2"],"prefix":"10.1128","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-1770","authenticated-orcid":true,"given":"Halie M.","family":"Rando","sequence":"first","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA"},{"name":"Center for Health AI, University of Colorado School of Medicine, Aurora, Colorado, USA"},{"name":"Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9668-3368","authenticated-orcid":true,"given":"Ronan","family":"Lordan","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-3730","authenticated-orcid":true,"given":"Alexandra J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amruta","family":"Naik","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8955-7582","authenticated-orcid":true,"given":"Nils","family":"Wellhausen","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likhitha","family":"Kolla","sequence":"additional","affiliation":[{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COVID-19 Review Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5324-9833","authenticated-orcid":true,"given":"Anthony","family":"Gitter","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Medical Informatics, University of Wisconsin\u2014Madison, Madison, Wisconsin, USA"},{"name":"Morgridge Institute for Research, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-9213","authenticated-orcid":true,"given":"Casey S.","family":"Greene","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA"},{"name":"Center for Health AI, University of Colorado School of Medicine, Aurora, Colorado, USA"},{"name":"Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA"},{"name":"Childhood Cancer Data Lab, Alex\u2019s Lemonade Stand Foundation, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The COVID-19 Review Consortium includes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simina M.","family":"Boca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Boerckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brueffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Brian","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikta","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Ada","family":"Dattoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Dziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Gitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi Raj","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey S.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marouen Ben","family":"Guebila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Himmelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafisa M.","family":"Jadavji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Kamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Knyazev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likhitha","family":"Kolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Lordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Lubiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitayo","family":"Lukan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serghei","family":"Mangul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Manheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy D\u2019Agostino","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse G.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel I.","family":"Mundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amruta","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YoSon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane N.","family":"Rafizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath","family":"Ramsundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halie M.","family":"Rando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandipan","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rubinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamonica","family":"Shinholster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin N.","family":"Skelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusha","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Wellhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400472111"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00095-21"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00233-21"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2798-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00928-22"},{"key":"e_1_3_3_7_2","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. https:\/\/covid19.trackvaccines.org\/. Accessed 5 December 2022."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41562-021-01122-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc5312"},{"key":"e_1_3_3_10_2","unstructured":"World Health Organization. 14 July 2021. Vaccine efficacy effectiveness and protection. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/vaccine-efficacy-effectiveness-and-protection. Accessed 5 December 2022."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483"},{"key":"e_1_3_3_12_2","unstructured":"COVID-19 Review Consortium. 2021. Evolutionary and genomic analysis of SARS-CoV-2. Manubot."},{"key":"e_1_3_3_13_2","first-page":"S405","article-title":"Differences between clinical trial efficacy and real-world effectiveness","volume":"12","author":"Davidson MH","year":"2006","unstructured":"Davidson MH. 2006. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care 12:S405\u2013S411.","journal-title":"Am J Manag Care"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key109"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.07.021"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-1339-5_2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.24.3.611"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.11.003"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.03.032"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00594"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2660(05)54011-2"},{"key":"e_1_3_3_22_2","unstructured":"Barranco C. 28 September 2020. The first live attenuated vaccines. Nat Res. https:\/\/www.nature.com\/articles\/d42859-020-00008-5."},{"key":"e_1_3_3_23_2","volume-title":"Molecular biology","author":"Flint J","year":"2015","unstructured":"Flint J, Skalka AM, Rall GF, Racaniello VR. 2015. Principles of virology, vol I. Molecular biology American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3035-9"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-35761-6.00002-X"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.602256"},{"key":"e_1_3_3_27_2","unstructured":"US Department of Health & Human Services. 2021. Vaccine types. https:\/\/www.hhs.gov\/immunization\/basics\/types\/index.html. Accessed 5 December 2022."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.11.022"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103841"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","unstructured":"Sharma S Vercruysse T Sanchez-Felipe L Kerstens W Rasulova M Abdelnabi R Foo CS Lemmens V Van Looveren D Maes P Baele G Weynand B Lemey P Neyts J Thibaut HJ Dallmeier K. 16 February 2022. Updated vaccine protects from infection with SARS-CoV-2 variants prevents transmission and is immunogenic against Omicron in hamsters. bioRxiv. doi:10.1101\/2021.11.12.468374.","DOI":"10.1101\/2021.11.12.468374"},{"key":"e_1_3_3_31_2","unstructured":"Marshall D. 23 April 2020. Griffith University researchers on the road to COVID-19 vaccine. https:\/\/news.griffith.edu.au\/2020\/04\/23\/griffith-university-researchers-on-the-road-to-covid-19-vaccine\/. Accessed 5 December 2022."},{"key":"e_1_3_3_32_2","unstructured":"Milken Institute. COVID-19 Treatment and Vaccine Tracker. https:\/\/milkeninstitute.org\/sites\/default\/files\/2020-03\/Covid19%20Tracker_WEB.pdf. Accessed 5 August 2022."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102775118"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1155761"},{"key":"e_1_3_3_35_2","unstructured":"Codagenix Inc. 2022. First-in-human randomised double-blind placebo-controlled dose-escalation study in healthy young adults evaluating the safety and immunogenicity of COVI-VAC a live attenuated vaccine candidate for prevention of COVID-19. NCT04619628. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04619628."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.775"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-022-01945-5"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00509-6"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02881"},{"key":"e_1_3_3_40_2","unstructured":"Meissa Vaccines Inc. 2022. Phase 1 open-label dose-escalation study to evaluate tolerability safety and immunogenicity of an intranasal live attenuated respiratory syncytial virus vaccine expressing spike protein of SARS-CoV-2 in healthy adults ages 18\u201369 years. NCT04798001. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04798001."},{"key":"e_1_3_3_41_2","unstructured":"Rando HM Greene CS Robson MP Boca SM Wellhausen N Lordan R Brueffer C Ray S D\u2019Agostino McGowan L Gitter A Dattoli AA Velazquez R Barton JP Field JM Ramsundar B MacLean AL Lee AJ Immunology Institute of the Icahn School ofMedicine Hu F Jadavji NM Sell E Wang J Rafizadeh DN Skelly AN Ben Guebila M Kolla L Manheim D Ghosh S Byrd JB Park Y Bansal V Capone S Dziak JJ Sun Y Qi Y Shinholster L Lukan T Knyazev S Perrin D Mangul S Das S Szeto GL Lubiana T Mai D Goel RR Boerckel JD Naik A Sun Y Himmelstein DS Kamil JP Meyer JG Mundo AI COVID-19 Review Consortium. 2023. SARS-CoV-2 and COVID-19: an evolving review of diagnostics and therapeutics. Manubot. https:\/\/greenelab.github.io\/covid19-review\/."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0337-y"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac182"},{"key":"e_1_3_3_44_2","unstructured":"Murdoch Childrens Research Institute. BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial. NCT04327206. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04327206. Accessed 8 February 2021."},{"key":"e_1_3_3_45_2","unstructured":"Texas A&M University. Bacillus Calmette-Guerin vaccination as defense against SARS-CoV-2: a randomized controlled trial to protect health care workers by enhanced trained immune responses. NCT04348370. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04348370. Accessed 8 February 2021."},{"key":"e_1_3_3_46_2","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. Codagenix Inc: COVI-VAC. https:\/\/covid19.trackvaccines.org\/vaccines\/59\/. Accessed 16 January 2023."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2007.10.010"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1357471"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2868"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.03.025"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.164.4.1114"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/1751-7915.13818"},{"key":"e_1_3_3_53_2","unstructured":"Reuters. 30 December 2020. China gives its first COVID-19 vaccine approval to Sinopharm. Reuters London United Kingdom. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/china-gives-its-first-covid-19-vaccine-approval-sinopharm-2020-12-31\/."},{"key":"e_1_3_3_54_2","unstructured":"Wee S-L Sim\u00f5es M. 16 July 2020. In coronavirus vaccine race China strays from the official paths. The New York Times New York NY. https:\/\/www.nytimes.com\/2020\/07\/16\/business\/china-vaccine-coronavirus.html."},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-03626-1"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.492"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh143"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00462-y"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.6b00006"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1177688"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00554-20"},{"key":"e_1_3_3_62_2","unstructured":"World Health Organization. 1 June 2021. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19. https:\/\/www.who.int\/publications-detail-redirect\/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1. Accessed 5 December 2022."},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30987-7"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1932"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30843-4"},{"key":"e_1_3_3_66_2","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. Sinovac: CoronaVac. https:\/\/covid19.trackvaccines.org\/vaccines\/7\/. Accessed 5 December 2022."},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab823"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01429-X"},{"key":"e_1_3_3_69_2","unstructured":"Corum J Zimmer C. 7 May 2021. How the Sinovac vaccine works. The New York Times New York NY. https:\/\/www.nytimes.com\/interactive\/2020\/health\/sinovac-covid-19-vaccine.html."},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04775-4"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3822780"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01469-5"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00319-4"},{"key":"e_1_3_3_74_2","unstructured":"Reuters. 23 December 2020. Brazil institute says CoronaVac efficacy above 50% delays full results. Reuters London United Kingdom. https:\/\/www.reuters.com\/article\/us-health-coronavirus-sinovac-butantan\/brazil-institute-says-coronavac-efficacy-above-50-delays-full-results-idUKKBN28X2FC."},{"key":"e_1_3_3_75_2","unstructured":"Zimmer C Londo\u00f1o E. 25 December 2020. Turkey and Brazil say Chinese vaccine effective with sparse supporting data. The New York Times New York NY. https:\/\/www.nytimes.com\/2020\/12\/25\/health\/turkey-brazil-sinovac-coronavirus-vaccine.html."},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107715"},{"key":"e_1_3_3_77_2","unstructured":"Zimmer C Corum J Wee S-L Kristoffersen M. 2020. Coronavirus vaccine tracker. The New York Times New York NY. https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html."},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9673453"},{"key":"e_1_3_3_79_2","unstructured":"Wee S-L. 16 September 2021. They relied on Chinese vaccines. Now they\u2019re battling outbreaks. The New York Times New York NY. https:\/\/www.nytimes.com\/2021\/06\/22\/business\/economy\/china-vaccines-covid-outbreak.html."},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00568-5"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1041"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103022"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2022.100153"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.939311"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.03.21261544"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00681-2"},{"key":"e_1_3_3_87_2","unstructured":"Medical Xpress. 11 August 2021. China approves first mixed-vaccine trial as Delta spreads. https:\/\/medicalxpress.com\/news\/2021-08-china-mixed-vaccine-trial-delta.html. Accessed 5 December 2022."},{"key":"e_1_3_3_88_2","unstructured":"Araos R. 2021. Reactogenicidad seguridad e inmunogenicidad de dosis de refuerzo de vacunas contra SARS-CoV-2 en Chile (Estudio REFUERZO). NCT04992182. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04992182."},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01677-z"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01705-6"},{"key":"e_1_3_3_91_2","unstructured":"World Health Organization. 10 June 2022. The Sinovac-CoronaVac COVID-19 vaccine: what you need to know. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-sinovac-covid-19-vaccine-what-you-need-to-know. Accessed 5 December 2022."},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00292-w"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.008"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30831-8"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15543"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8565"},{"key":"e_1_3_3_97_2","unstructured":"Reuters. 29 December 2020. Sinopharm\u2019s COVID-19 vaccine 79% effective seeks approval in China. Reuters London United Kingdom. https:\/\/www.reuters.com\/article\/health-coronavirus-china-vaccine-int\/sinopharms-covid-19-vaccine-79-effective-seeks-approval-in-china-idUSKBN2940CA."},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.15.21260621"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","unstructured":"Huang B Dai L Wang H Hu Z Yang X Tan W Gao GF. 2 February 2021. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv. doi:10.1101\/2021.02.01.429069.","DOI":"10.1101\/2021.02.01.429069"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-022-00373-7"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102054"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21639-w"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30942-7"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00070-0"},{"key":"e_1_3_3_105_2","unstructured":"Bharat Biotech. 2021. Bharat Biotech announces phase 3 results of COVAXIN. Bharat Biotech Hyderabad India. https:\/\/www.bharatbiotech.com\/images\/press\/covaxin-phase3-efficacy-results.pdf."},{"key":"e_1_3_3_106_2","unstructured":"Biogenetech. 2021. Ocugen\u2019s COVID-19 vaccine co-development partner Bharat Biotech shares phase 3 interim results of COVAXIN demonstrates efficacy of 81%. Biogenetech. https:\/\/www.biogenetech.co.th\/wp-content\/uploads\/2021\/03\/5-Ocugen.pdf."},{"key":"e_1_3_3_107_2","unstructured":"Xinhuanet. 4 March 2021. Zimbabwe authorizes use of India\u2019s first indigenous COVID-19 vaccine. http:\/\/www.xinhuanet.com\/english\/2021-03\/04\/c_139783893.htm. Accessed 5 December 2022."},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02000-6"},{"key":"e_1_3_3_109_2","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. Bharat Biotech: Covaxin. https:\/\/covid19.trackvaccines.org\/vaccines\/9\/. Accessed 5 December 2022."},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab154"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab104"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab051"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.24.22269189"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.03.016"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.53411\/jpadr.2021.2.3.5"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27655"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01226-8"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2034456"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.26.21262705"},{"key":"e_1_3_3_120_2","unstructured":"Hindustan Times. 7 July 2021. Covaxin booster dose: what is it? What does govt say about this? Hindustan Times New Delhi India. https:\/\/www.hindustantimes.com\/india-news\/covaxin-booster-dose-what-is-it-what-does-govt-say-about-this-101625644184446.html. Accessed 5 December 2022."},{"key":"e_1_3_3_121_2","unstructured":"Das S. 25 September 2021. Booster dose: Bharat Biotech\u2019s nasal vaccine may be used with Covaxin. Business Standard New Delhi India. https:\/\/www.business-standard.com\/article\/current-affairs\/booster-dose-bharat-biotech-s-nasal-vaccine-may-be-used-with-covaxin-121092500034_1.html. Accessed 5 December 2022."},{"key":"e_1_3_3_122_2","unstructured":"Bharadwaj S. 21 September 2021. Covaxin kids trial over Bharat Biotech to submit data to DCGI next week. The Times of India. https:\/\/timesofindia.indiatimes.com\/india\/bharat-biotech-to-submit-covaxin-kids-trials-data-to-dcgi-in-weeks-time\/articleshow\/86392325.cms."},{"key":"e_1_3_3_123_2","unstructured":"India Today. 24 September 2021. WHO emergency approval for Covaxin delayed till October 5. India Today New Delhi India. https:\/\/www.indiatoday.in\/coronavirus-covid-19-outbreak\/video\/who-emergency-approval-for-covaxin-delayed-till-october-1856178-2021-09-23. Accessed 5 December 2022."},{"key":"e_1_3_3_124_2","unstructured":"World Health Organization. 2 April 2022. Suspension of supply of COVID-19 vaccine (COVAXIN\u00ae). https:\/\/extranet.who.int\/pqweb\/vaccines\/suspension-supply-covid-19-vaccine-covaxin. Accessed 5 December 2022."},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o902"},{"key":"e_1_3_3_126_2","unstructured":"PTI. 24 May 2022. FDA lifts hold on Bharat Biotech\u2019s Covaxin clinical trials in US. Business Today. https:\/\/www.businesstoday.in\/coronavirus\/story\/fda-lifts-hold-on-bharat-biotechs-covaxin-clinical-trials-in-us-334915-2022-05-24. Accessed 16 January 2023."},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1163\/25895893-bja10009"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02288-1"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02286-8"},{"key":"e_1_3_3_130_2","unstructured":"World Health Organization. 2022. The Valneva VLA2001 COVID-19 vaccine: what you need to know. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-valneva-vla2001-covid-19-vaccine--what-you-need-to-know. Accessed 1 December 2022."},{"key":"e_1_3_3_131_2","unstructured":"World Health Organization. 10 June 2022. The Bharat Biotech BBV152 COVAXIN vaccine against COVID-19: what you need to know. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-bharat-biotech-bbv152-covaxin-vaccine-against-covid-19-what-you-need-to-know. Accessed 5 December 2022."},{"key":"e_1_3_3_132_2","unstructured":"WHO Collaborating Centre for Vaccine Safety. 20 September 2022. Is the Sinopharm BIBP (Covilo) COVID-19 vaccine safe and effective? https:\/\/www.covid19infovaccines.com\/en-posts\/is-the-sinopharm-bibp-covilo-covid-19-vaccine-safe-and-effective. Accessed 5 December 2022."},{"key":"e_1_3_3_133_2","unstructured":"World Health Organization. 3 June 2022. COVID-19 vaccine (Vero cell) inactivated (Sinopharm). https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/covid-19\/16-june-22080-sinopharm-vaccine-explainer-update.pdf. Accessed 5 December 2022."},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.3390\/v14092016"},{"key":"e_1_3_3_135_2","unstructured":"Sattwika PD. 2022. A phase II non-randomized open labelled clinical trial to evaluate the safety & immunogenicity of SARS-COV-2 vaccine (Vero cell) inactivated as a booster dose. NCT05172193. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05172193."},{"key":"e_1_3_3_136_2","unstructured":"China National Biotec Group Company Limited. 2022. Multicenter randomized double blind parallel placebo controlled phase III clinical trial to evaluate the protective efficacy safety and immunogenicity of inactivated SARS-CoV-2 vaccines (Vero cell) in healthy population aged 18 years old and above. NCT04510207. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04510207."},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27396"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1402981111"},{"key":"e_1_3_3_139_2","first-page":"159","volume-title":"Subunit vaccine delivery. Advances in delivery science and technology.","author":"Donaldson B","year":"2014","unstructured":"Donaldson B, Al-Barwani F, Young V, Scullion S, Ward V, Young S. 2014. Virus-like particles, a versatile subunit vaccine platform, p 159\u2013180. In Foged C, Rades T, Perrie Y, Hook S (ed), Subunit vaccine delivery. Advances in delivery science and technology. Springer, New York, NY."},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0966-842x(03)00208-7"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.01.001"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-00806-7"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-1823-5"},{"key":"e_1_3_3_144_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines2030515"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.573624"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.055"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.46.3.280"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00083-06"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2012.0076"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.01.059"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.10.031"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.05.003"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2009.0090"},{"key":"e_1_3_3_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.06.084"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2005.24.510"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.8.3718-3726.2005"},{"key":"e_1_3_3_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.05.073"},{"key":"e_1_3_3_158_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.01.058"},{"key":"e_1_3_3_159_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00298"},{"key":"e_1_3_3_160_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.27464"},{"key":"e_1_3_3_161_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.08.031"},{"key":"e_1_3_3_162_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112602"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.065"},{"key":"e_1_3_3_164_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2016.10.005"},{"key":"e_1_3_3_165_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1707304114"},{"key":"e_1_3_3_166_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2014.0080"},{"key":"e_1_3_3_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.064"},{"key":"e_1_3_3_168_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8712"},{"key":"e_1_3_3_169_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.07.015"},{"key":"e_1_3_3_170_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.003"},{"key":"e_1_3_3_171_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.04.016"},{"key":"e_1_3_3_172_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8475"},{"key":"e_1_3_3_173_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-018-0064-8"},{"key":"e_1_3_3_174_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-020-00695-2"},{"key":"e_1_3_3_175_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-1656(99)00107-8"},{"key":"e_1_3_3_176_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01339-14"},{"key":"e_1_3_3_177_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003418"},{"key":"e_1_3_3_178_2","doi-asserted-by":"publisher","DOI":"10.1188\/06.CJON.559-560"},{"key":"e_1_3_3_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2014.12.006"},{"key":"e_1_3_3_180_2","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. Vaccines candidates in clinical trials. https:\/\/covid19.trackvaccines.org\/vaccines\/. Accessed 5 December 2022."},{"key":"e_1_3_3_181_2","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2016.1191707"},{"key":"e_1_3_3_182_2","unstructured":"World Health Organization. The Novavax vaccine against COVID-19: what you need to know. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-novavax-vaccine-against-covid-19-what-you-need-to-know. Accessed 16 January 2023."},{"key":"e_1_3_3_183_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026920"},{"key":"e_1_3_3_184_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20653-8"},{"key":"e_1_3_3_185_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.iecr.8b00985"},{"key":"e_1_3_3_186_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660198"},{"key":"e_1_3_3_187_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659"},{"key":"e_1_3_3_188_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116185"},{"key":"e_1_3_3_189_2","unstructured":"Allen A Tribble SJ. 4 June 2022. Novavax missed its global moonshot but is angling to win over mRNA defectors. ASBMB Today Rockville MD. https:\/\/www.asbmb.org\/asbmb-today\/industry\/060422\/novavax-missed-its-global-moonshot-but-is-angling. Accessed 16 January 2023."},{"key":"e_1_3_3_190_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2965"},{"key":"e_1_3_3_191_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc9588"},{"key":"e_1_3_3_192_2","unstructured":"Owermohle S Banco E Cancryn A. 19 October 2021. \u2018They rushed the process\u2019: vaccine maker\u2019s woes hamper global inoculation campaign. POLITICO Arlington VA. https:\/\/www.politico.com\/news\/2021\/10\/19\/novavax-vaccine-rush-process-global-campaign-516298. Accessed 16 January 2023."},{"key":"e_1_3_3_193_2","unstructured":"Kimball S. 13 May 2022. Novavax confident Covid vaccine will receive FDA authorization in June after delays. CNBC. https:\/\/www.cnbc.com\/2022\/05\/13\/novavax-confident-covid-vaccine-will-receive-fda-authorization-in-june-after-delays.html. Accessed 16 January 2023."},{"key":"e_1_3_3_194_2","unstructured":"World Health Organization. 17 December 2021. WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries. https:\/\/www.who.int\/news\/item\/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries. Accessed 16 January 2023."},{"key":"e_1_3_3_195_2","unstructured":"Medicines and Healthcare Products Regulatory Agency. 3 February 2022. Novavax COVID-19 vaccine Nuvaxovid approved by MHRA. Medicines and Healthcare Products Regulatory Agency London United Kingdom. https:\/\/www.gov.uk\/government\/news\/novavax-covid-19-vaccine-nuvaxovid-approved-by-mhra. Accessed 5 December 2022."},{"key":"e_1_3_3_196_2","unstructured":"European Medicines Agency. 20 December 2021. EMA recommends Nuvaxovid for authorisation in the EU. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-nuvaxovid-authorisation-eu."},{"key":"e_1_3_3_197_2","unstructured":"FDA. 13 July 2022. Coronavirus (COVID-19) update: FDA authorizes emergency use of Novavax COVID-19 vaccine adjuvanted. FDA Silver Spring MD. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted. Accessed 5 December 2022."},{"key":"e_1_3_3_198_2","unstructured":"Reuters. 22 November 2022. Gavi rejects Novavax\u2019s claim on COVID vaccine deal breach. Reuters London United Kingdom. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/gavi-says-it-is-not-breach-novavax-vaccine-deal-2022-11-22\/."},{"key":"e_1_3_3_199_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103055"},{"key":"e_1_3_3_200_2","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.23.21267374"},{"key":"e_1_3_3_201_2","unstructured":"Novavax. 2022. A 2-part phase 1\/2 randomized observer-blinded study to evaluate the safety and immunogenicity of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with or without MATRIX-M\u2122 adjuvant in healthy subjects. NCT04368988. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368988."},{"key":"e_1_3_3_202_2","doi-asserted-by":"publisher","unstructured":"Bhiman JN Richardson SI Lambson BE Kgagudi P Mzindle N Kaldine H Crowther C Gray G Bekker L-G Shinde V Bennett C Glenn GM Madhi S Moore PL. 17 July 2022. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages. bioRxiv. doi:10.1101\/2022.07.14.500148.","DOI":"10.1101\/2022.07.14.500148"},{"key":"e_1_3_3_203_2","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.09.21258556"},{"key":"e_1_3_3_204_2","unstructured":"Novavax. 8 September 2021. Novavax initiates phase 1\/2 clinical trial of combination vaccine for COVID-19 and seasonal influenza. Novavax Gaithersburg MD. https:\/\/ir.novavax.com\/2021-09-08-Novavax-Initiates-Phase-1-2-Clinical-Trial-of-Combination-Vaccine-for-COVID-19-and-Seasonal-Influenza. Accessed 5 December 2022."},{"key":"e_1_3_3_205_2","doi-asserted-by":"publisher","unstructured":"Massare MJ Patel N Zhou B Maciejewski S Flores R Guebre-Xabier M Tian J-H Portnoff AD Fries L Shinde V Ellingsworth L Glenn G Smith G. 5 May 2021. Combination respiratory vaccine containing recombinant SARS-CoV-2 spike and quadrivalent seasonal influenza hemagglutinin nanoparticles with Matrix-M adjuvant. bioRxiv. doi:10.1101\/2021.05.05.442782.","DOI":"10.1101\/2021.05.05.442782"},{"key":"e_1_3_3_206_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-03470-x"},{"key":"e_1_3_3_207_2","doi-asserted-by":"publisher","DOI":"10.37757\/mr2022.v24.n3-4.13"},{"key":"e_1_3_3_208_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100423"},{"key":"e_1_3_3_209_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2022.08.001"},{"key":"e_1_3_3_210_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbt.2022.08.002"},{"key":"e_1_3_3_211_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101383"},{"key":"e_1_3_3_212_2","unstructured":"Xinhuanet. 20 March 2021. Cuba\u2019s Abdala COVID-19 vaccine enters phase 3 clinical trial. http:\/\/www.xinhuanet.com\/english\/northamerica\/2021-03\/20\/c_139823225.htm. Accessed 16 January 2023."},{"key":"e_1_3_3_213_2","unstructured":"Reuters. 22 June 2021. Cuba says Abdala vaccine 92.28% effective against coronavirus. Reuters London United Kingdom. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/cuba-says-abdala-vaccine-9228-effective-against-coronavirus-2021-06-21\/."},{"key":"e_1_3_3_214_2","unstructured":"Hern\u00e1ndez LM Le\u00f3n RT. 21 June 2021. Abdala con tres dosis tiene una eficacia de 92 28%. Granma Havana Cuba. https:\/\/www.granma.cu\/cuba\/2021-06-21\/abdala-con-tres-dosis-tiene-una-eficacia-de-9228-porciento-21-06-2021-21-06-01. Accessed 22 December 2022."},{"key":"e_1_3_3_215_2","unstructured":"OnCuba Staff. 27 June 2021. How was the efficacy of the Cuban COVID-19 vaccine candidates calculated? OnCubaNews English. https:\/\/oncubanews.com\/en\/cuba\/how-was-the-efficacy-of-the-cuban-covid-19-vaccine-candidates-calculated\/. Accessed 16 January 2023."},{"key":"e_1_3_3_216_2","unstructured":"CECMED. 9 July 2021. Aprueba el CECMED el Autorizo de Uso de Emergencia del candidato vacunal cubano ABDALA. https:\/\/www.cecmed.cu\/noticias\/aprueba-cecmed-autorizo-uso-emergencia-candidato-vacunal-cubano-abdala. Accessed 22 December 2022."},{"key":"e_1_3_3_217_2","unstructured":"Taylor L. 23 December 2021. Cuba\u2019s home-grown vaccines have massively cut covid-19 cases. New Scientist. https:\/\/www.newscientist.com\/article\/2303121-cubas-home-grown-vaccines-have-massively-cut-covid-19-cases. Accessed 13 January 2023."},{"key":"e_1_3_3_218_2","doi-asserted-by":"publisher","DOI":"10.1101\/2022.09.08.22279690"},{"key":"e_1_3_3_219_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100366"},{"key":"e_1_3_3_220_2","unstructured":"Ministerio de Salud P\u00fablica de Cuba. 2023. Actualizaci\u00f3n de la estrategia para el desarrollo de las vacunas cubanas. Ministerio de Salud P\u00fablica de Cuba Havana Cuba. https:\/\/salud.msp.gob.cu\/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria\/."},{"key":"e_1_3_3_221_2","doi-asserted-by":"publisher","DOI":"10.37757\/MR2022.V24.N1.11"},{"key":"e_1_3_3_222_2","unstructured":"World Health Organization. 2021. Status of COVID-19 vaccines within WHO EUL\/PQ evaluation process. https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/Status_COVID_VAX_12January2023.pdf."},{"key":"e_1_3_3_223_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o230"},{"key":"e_1_3_3_224_2","article-title":"Variantes \u00f3micron y delta de SARS-CoV-2 conservan ep\u00edtopes presentes en vacunas cubanas anti-covid-19 Abdala y Soberana","volume":"47","author":"Serrano-Barrera OR","year":"2022","unstructured":"Serrano-Barrera OR, Bello-Rodr\u00edguez MM, Pupo-Rodr\u00edguez OL, Robinson-Agramonte M, de los A, P\u00e9rez O. 2022. Variantes \u00f3micron y delta de SARS-CoV-2 conservan ep\u00edtopes presentes en vacunas cubanas anti-covid-19 Abdala y Soberana. Revista Electr\u00f3nica Dr Zoilo E Marinello Vidaurreta 47:e299.","journal-title":"Revista Electr\u00f3nica Dr Zoilo E Marinello Vidaurreta"},{"key":"e_1_3_3_225_2","unstructured":"EFE. 13 October 2021. Cuba to apply booster doses of its COVID-19 vaccines. OnCubaNews English. https:\/\/oncubanews.com\/en\/coronavirus\/cuba-to-apply-booster-doses-of-its-covid-19-vaccines\/. Accessed 16 January 2023."},{"key":"e_1_3_3_226_2","unstructured":"Meredith S. 13 January 2022. Why Cuba\u2019s extraordinary Covid vaccine success could provide the best hope for low-income countries. CNBC. https:\/\/www.cnbc.com\/2022\/01\/13\/why-cubas-extraordinary-covid-vaccine-success-could-provide-the-best-hope-for-the-global-south.html. Accessed 16 January 2023."},{"key":"e_1_3_3_227_2","unstructured":"Frank M Sherwood D. 29 December 2021. Cuba to fast-track boosters as Omicron looms. Reuters London United Kingdom. https:\/\/www.reuters.com\/world\/americas\/cuba-fast-track-boosters-omicron-looms-2021-12-29\/."},{"key":"e_1_3_3_228_2","unstructured":"Worldometer. Cuba COVID. Coronavirus statistics. https:\/\/www.worldometers.info\/coronavirus\/country\/cuba. Accessed 16 January 2023."},{"key":"e_1_3_3_229_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1912"},{"key":"e_1_3_3_230_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1095992"},{"key":"e_1_3_3_231_2","unstructured":"Medicago. Covifenz\u00ae. Medicago Quebec Canada. https:\/\/medicago.com\/en\/our-products\/our-vaccines\/covifenz-covid-19-vlp-vaccine\/. Accessed 5 December 2022."},{"key":"e_1_3_3_232_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32014-6"},{"key":"e_1_3_3_233_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01370-1"},{"key":"e_1_3_3_234_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.192"},{"key":"e_1_3_3_235_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201300"},{"key":"e_1_3_3_236_2","unstructured":"GSK. 24 February 2022. Medicago and GSK announce the approval by Health Canada of COVIFENZ an adjuvanted plant-based COVID-19 vaccine. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/medicago-and-gsk-announce-the-approval-by-health-canada-of-covifenz\/. Accessed 5 December 2022."},{"key":"e_1_3_3_237_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-7652.2008.00384.x"},{"key":"e_1_3_3_238_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o811"},{"key":"e_1_3_3_239_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22218"},{"key":"e_1_3_3_240_2","unstructured":"Lam P. 29 December 2022. Big Tobacco\u2019s divestment from Quebec\u2019s Medicago \u2018a step in the right direction\u2019 for its COVID vaccine. CBC News Toronto Canada. https:\/\/www.cbc.ca\/news\/health\/philips-morris-divestment-medicago-1.6700103. Accessed 16 January 2023."},{"key":"e_1_3_3_241_2","unstructured":"Government of Canada. 2022. COVID-19 vaccine: Canadian immunization guide. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-26-covid-19-vaccine.html. Accessed 22 December 2022."},{"key":"e_1_3_3_242_2","unstructured":"Medicago. News releases. https:\/\/medicago.com\/en\/news-releases\/. Accessed 16 January 2023."},{"key":"e_1_3_3_243_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2021.101606"},{"key":"e_1_3_3_244_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00507-8"},{"key":"e_1_3_3_245_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-01756-0"},{"key":"e_1_3_3_246_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab213"},{"key":"e_1_3_3_247_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100674"},{"key":"e_1_3_3_248_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe2803"},{"key":"e_1_3_3_249_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf1374"},{"key":"e_1_3_3_250_2","unstructured":"Mathieu E Ritchie H Rod\u00e9s-Guirao L Appel C Giattino C Hasell J Macdonald B Dattani S Beltekian D Ortiz-Ospina E Roser M. 2020. Coronavirus pandemic (COVID-19). Our World in Data. https:\/\/ourworldindata.org\/coronavirus."},{"key":"e_1_3_3_251_2","unstructured":"Holder J. 2021. Tracking coronavirus vaccinations around the world. The New York Times New York NY. https:\/\/www.nytimes.com\/interactive\/2021\/world\/covid-vaccinations-tracker.html."},{"key":"e_1_3_3_252_2","unstructured":"Goodman PS. 25 December 2020. One vaccine side effect: global economic inequality. The New York Times New York NY. https:\/\/www.nytimes.com\/2020\/12\/25\/business\/coronavirus-vaccines-global-economy.html."},{"key":"e_1_3_3_253_2","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12503"},{"key":"e_1_3_3_254_2","unstructured":"World Health Organization. 9 September 2020. Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility. https:\/\/www.who.int\/publications\/m\/item\/fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-facility. Accessed 5 December 2022."},{"key":"e_1_3_3_255_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.369.6503.489"},{"key":"e_1_3_3_256_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01367-2"},{"key":"e_1_3_3_257_2","unstructured":"Twohey M Collins K Thomas K. 2020. With first dibs on vaccines rich countries have \u2018cleared the shelves.\u2019 The New York Times New York NY. https:\/\/www.nytimes.com\/2020\/12\/15\/us\/coronavirus-vaccine-doses-reserved.html."},{"key":"e_1_3_3_258_2","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.3341"},{"key":"e_1_3_3_259_2","unstructured":"Mwai P. 31 December 2021. Covid-19 vaccinations: African nations miss WHO target. BBC News. https:\/\/www.bbc.com\/news\/56100076."},{"key":"e_1_3_3_260_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4853"},{"key":"e_1_3_3_261_2","unstructured":"World Health Organization. COVAX. Working toward for global equitable access to COVID-19 vaccines. https:\/\/www.who.int\/initiatives\/act-accelerator\/covax. Accessed 5 December 2022."},{"key":"e_1_3_3_262_2","unstructured":"Gavi. COVAX vaccine roll-out. https:\/\/www.gavi.org\/covax-vaccine-roll-out. Accessed 5 December 2022."},{"key":"e_1_3_3_263_2","unstructured":"Cohen J Kupferschmidt K. 9 March 2021. Countries now scrambling for COVID-19 vaccines may soon have surpluses to donate. American Association for the Advancement of Science (AAAS) Washington DC. https:\/\/www.science.org\/content\/article\/countries-now-scrambling-covid-19-vaccines-may-soon-have-surpluses-donate."},{"key":"e_1_3_3_264_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6959"},{"key":"e_1_3_3_265_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78447-3"},{"key":"e_1_3_3_266_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.12.059"},{"key":"e_1_3_3_267_2","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-107036"},{"key":"e_1_3_3_268_2","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.12.21249694"},{"key":"e_1_3_3_269_2","unstructured":"Ferran M. 19 January 2022. CORBEVAX a new patent-free COVID-19 vaccine could be a pandemic game changer globally. The Conversation. http:\/\/theconversation.com\/corbevax-a-new-patent-free-covid-19-vaccine-could-be-a-pandemic-game-changer-globally-174672. Accessed 16 January 2023."},{"key":"e_1_3_3_270_2","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. Biological E Limited: Corbevax. https:\/\/covid19.trackvaccines.org\/vaccines\/54\/. Retrieved 16 January 2023."},{"key":"e_1_3_3_271_2","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihab010"},{"key":"e_1_3_3_272_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-01974-3"},{"key":"e_1_3_3_273_2","unstructured":"Sguazzin A. 3 January 2021. Africa left with few options for vaccines South Africa says. Bloomberg. https:\/\/www.bloomberg.com\/news\/articles\/2021-01-03\/pfizer-to-supply-african-health-care-workers-with-vaccines. Accessed 13 January 2023."},{"key":"e_1_3_3_274_2","unstructured":"UNICEF. COVAX: ensuring global equitable access to COVID-19 vaccines. https:\/\/www.unicef.org\/supply\/covax-ensuring-global-equitable-access-covid-19-vaccines. Accessed 16 January 2023."},{"key":"e_1_3_3_275_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00328-2"},{"key":"e_1_3_3_276_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac361"},{"key":"e_1_3_3_277_2","doi-asserted-by":"publisher","DOI":"10.1080\/20477724.2022.2091862"},{"key":"e_1_3_3_278_2","unstructured":"Taylor A. 10 December 2021. Covax promised 2 billion vaccine doses to help the world\u2019s neediest in 2021. It won\u2019t deliver even half that. Washington Post Washington DC. https:\/\/www.washingtonpost.com\/world\/2021\/12\/10\/covax-doses-delivered\/."},{"key":"e_1_3_3_279_2","unstructured":"World Health Organization. Ten threats to global health in 2019. https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019. Accessed 16 January 2023."},{"key":"e_1_3_3_280_2","unstructured":"Hamel L Kirzinger A Lopes L Kearney A Sparks G Brodie M. 22 January 2021. KFF COVID-19 vaccine monitor: January 2021. KFF. https:\/\/www.kff.org\/coronavirus-covid-19\/report\/kff-covid-19-vaccine-monitor-january-2021\/. Accessed 16 January 2023."},{"key":"e_1_3_3_281_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMms2101220"},{"key":"e_1_3_3_282_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17022"},{"key":"e_1_3_3_283_2","doi-asserted-by":"publisher","DOI":"10.1177\/00333549221114346"},{"key":"e_1_3_3_284_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28156"},{"key":"e_1_3_3_285_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm9825"},{"key":"e_1_3_3_286_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41256-022-00255-1"},{"key":"e_1_3_3_287_2","doi-asserted-by":"publisher","DOI":"10.1080\/20477724.2021.2011580"},{"key":"e_1_3_3_288_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052432"},{"key":"e_1_3_3_289_2","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgac207"},{"key":"e_1_3_3_290_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01728-z"},{"key":"e_1_3_3_291_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268926"},{"key":"e_1_3_3_292_2","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdab122"},{"key":"e_1_3_3_293_2","doi-asserted-by":"publisher","DOI":"10.1177\/1075547020960463"},{"key":"e_1_3_3_294_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.02254"},{"key":"e_1_3_3_295_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13037-021-00291-9"},{"key":"e_1_3_3_296_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.035"},{"key":"e_1_3_3_297_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.09.006"},{"key":"e_1_3_3_298_2","unstructured":"Berg S. 20 July 2022. What sets apart Novavax option from other COVID-19 vaccines. American Medical Association Philadelphia PA. https:\/\/www.ama-assn.org\/delivering-care\/public-health\/what-sets-apart-novavax-option-other-covid-19-vaccines. Accessed 16 January 2023."},{"key":"e_1_3_3_299_2","unstructured":"Berman M Rupp R. 3 August 2022. Novavax COVID vaccine is for those hesitant to get vaccinated. The Daily News Galveston TX. https:\/\/www.galvnews.com\/health\/free\/novavax-covid-vaccine-is-for-those-hesitant-to-get-vaccinated\/article_8ddebef4-1db0-579a-b0d2-852f2031d881.html. Accessed 16 January 2023."},{"key":"e_1_3_3_300_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13661"},{"key":"e_1_3_3_301_2","unstructured":"Constantino AK. 15 July 2022. Novavax\u2019s new Covid vaccine is perfect for people scared of mRNA tech\u2014but it won\u2019t win over the unvaccinated. CNBC. https:\/\/www.cnbc.com\/2022\/07\/15\/why-new-novavax-covid-vaccine-wont-win-over-unvaccinated-americans.html. Accessed 16 January 2023."},{"key":"e_1_3_3_302_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.099"},{"key":"e_1_3_3_303_2","doi-asserted-by":"publisher","DOI":"10.3201\/1107.050219"},{"key":"e_1_3_3_304_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3143"},{"key":"e_1_3_3_305_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2005630"},{"key":"e_1_3_3_306_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1358325"},{"key":"e_1_3_3_307_2","unstructured":"Jordahl K Van Den Bossche J Fleischmann M McBride J Wasserman J Badaracco AG Gerard J Snow AD Tratner J Perry M Farmer C Hjelle GA Cochran M Gillies S Culbertson L Bartos M Ward B Caria G Taves M Eubank N Sangarshanan Flavin J Richards M Rey S Maxalbert Bilogur A Ren C Arribas-Bel D Mesejo-Le\u00f3n D Wasser L. 16 October 2021. geopandas\/geopandas: v0.10.2. Zenodo. https:\/\/doi.org\/gqkzpv."},{"key":"e_1_3_3_308_2","unstructured":"Kibirige H. 2022. plotnine. https:\/\/github.com\/has2k1\/plotnine. Accessed 5 December 2022."},{"key":"e_1_3_3_309_2","unstructured":"Wickham H Chang W Henry L Pedersen TL Takahashi K Wilke C Woo K Yutani H Dunnington D R Studio. Smoothed conditional means\u2014geom_smooth. https:\/\/ggplot2.tidyverse.org\/reference\/geom_smooth.html. Accessed 5 December 2022."},{"key":"e_1_3_3_310_2","unstructured":"Our World in Data. 2022. COVID-19 dataset by Our World in Data. https:\/\/github.com\/owid\/covid-19-data\/blob\/9e0b8314da28f155a88bbaf7617390c01c1c26da\/public\/data\/vaccinations\/locations.csv. Accessed 5 December 2022."},{"key":"e_1_3_3_311_2","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. Types of vaccines. https:\/\/covid19.trackvaccines.org\/types-of-vaccines\/. Accessed 5 December 2022."},{"key":"e_1_3_3_312_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1"},{"key":"e_1_3_3_313_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2122503"},{"key":"e_1_3_3_314_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111800"}],"container-title":["mSystems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/msystems.00927-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/msystems.00927-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T18:59:04Z","timestamp":1723402744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/msystems.00927-22"}},"subtitle":[],"editor":[{"given":"Jack A.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":313,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4,27]]}},"alternative-id":["10.1128\/msystems.00927-22"],"URL":"https:\/\/doi.org\/10.1128\/msystems.00927-22","relation":{},"ISSN":["2379-5077"],"issn-type":[{"value":"2379-5077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"2023-03-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00927-22"}}